Hyphens Pharma and Agency for Science, Technology and Research (A*STAR) inked a memorandum of understanding (MoU) on becoming strategic dialogue partners to explore collaboration in market-relevant projects in dermatology research and skin disorders.
Hyphens is currently licensing sugar-based surfactant micro-emulsions technology from A*STAR’s Institute of Chemical and Engineering Sciences (ICES). By leveraging A*STAR’s research and development capabilities, it is envisioned that this MoU will enable Hyphens to develop innovative and differentiated dermatological products to address unmet market needs.
Hyphens is a Singapore-headquartered ASEAN specialty pharma company. Operating in six countries across the region, Hyphens has a strong medical, regulatory and commercial capability. Dermatology is a key therapeutic focus field where Hyphens markets products under the brands “Ceradan” and “TDF”.
22nd Regional Conference of Dermatology (RCD 2016), 21-24 April 2016 – Raffles City Convention Centre, Singapore
Hyphens took centre stage as the sole Diamond Supporter of this event which drew more than 1,000 delegates from around the region.
We successfully achieved full house for two of our supported symposiums delivered by key speakers from Germany and Singapore. The first symposium was on the advancement in atopic dermatitis and COPES, featuring our study in collaboration with KK Women’s and Children’s Hospital and National Skin Centre (Ceradan®). The second symposium was on urticaria and the clinical relevance of PAF (Rupafin®).